UBS Group AG Sells 4,147 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

UBS Group AG decreased its stake in Revance Therapeutics, Inc. (NASDAQ:RVNCGet Rating) by 4.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,762 shares of the biopharmaceutical company’s stock after selling 4,147 shares during the period. UBS Group AG owned 0.11% of Revance Therapeutics worth $2,234,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Mark Sheptoff Financial Planning LLC purchased a new stake in Revance Therapeutics in the third quarter worth $54,000. Advisor Group Holdings Inc. raised its stake in Revance Therapeutics by 60.6% in the 1st quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 1,071 shares during the period. Quantbot Technologies LP purchased a new stake in Revance Therapeutics during the third quarter valued at about $138,000. Point72 Hong Kong Ltd purchased a new position in shares of Revance Therapeutics in the second quarter worth about $92,000. Finally, Exencial Wealth Advisors LLC bought a new stake in shares of Revance Therapeutics in the third quarter valued at approximately $244,000. 82.68% of the stock is currently owned by hedge funds and other institutional investors.

Revance Therapeutics Trading Down 0.4 %

NASDAQ RVNC opened at $32.99 on Tuesday. The stock has a market cap of $2.73 billion, a P/E ratio of -6.86 and a beta of 0.86. The stock has a 50 day simple moving average of $29.83 and a two-hundred day simple moving average of $25.60. Revance Therapeutics, Inc. has a fifty-two week low of $11.27 and a fifty-two week high of $36.61. The company has a debt-to-equity ratio of 30.11, a quick ratio of 4.71 and a current ratio of 4.95.

Revance Therapeutics (NASDAQ:RVNCGet Rating) last announced its earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.78). Revance Therapeutics had a negative net margin of 268.87% and a negative return on equity of 786.70%. The company had revenue of $49.90 million for the quarter, compared to the consensus estimate of $45.10 million. During the same period in the previous year, the firm posted ($0.93) EPS. The company’s revenue for the quarter was up 92.7% on a year-over-year basis. On average, analysts forecast that Revance Therapeutics, Inc. will post -2.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on RVNC shares. Guggenheim raised their price objective on shares of Revance Therapeutics to $36.00 in a report on Tuesday, November 15th. HC Wainwright restated a “buy” rating and set a $42.00 price target on shares of Revance Therapeutics in a research report on Wednesday, March 1st. Piper Sandler upped their price objective on shares of Revance Therapeutics from $29.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 31st. Barclays raised their price target on Revance Therapeutics from $37.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, March 1st. Finally, Morgan Stanley upped their target price on Revance Therapeutics from $25.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 24th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.09.

Insider Activity

In other Revance Therapeutics news, CFO Tobin Schilke sold 3,201 shares of the stock in a transaction on Wednesday, February 1st. The stock was sold at an average price of $34.60, for a total value of $110,754.60. Following the completion of the transaction, the chief financial officer now owns 54,676 shares in the company, valued at $1,891,789.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 11,103 shares of company stock worth $349,507 in the last quarter. 5.10% of the stock is owned by company insiders.

Revance Therapeutics Company Profile

(Get Rating)

Revance Therapeutics, Inc is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders.

Featured Articles

Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics, Inc. (NASDAQ:RVNCGet Rating).

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.